2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u v [w] x y z

Abstract Number: 157

We Can Do Better: Evaluating Inpatient Pediatric Rheumatology Inpatient/Consult Service Performance
Abstract Number: 2827

Weight Fluctuation and Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis
Abstract Number: 1799

Wellness and Resiliency Among Recent Rheumatology Fellowship Graduates: A Qualitative Study
Abstract Number: 2211

What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT- scan in Patients with Ankylosing Spondylitis?
Abstract Number: 2244

What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Abstract Number: 2763

What Disease Do You Have? – Assessment and Predictors of Accurate Illness Naming in Rheumatology
Abstract Number: 2511

What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
Abstract Number: 2186

What Is an Important Difference in Gait Speed in Adults with Knee Osteoarthritis?
Abstract Number: 2777

What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts
Abstract Number: 445

What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis
Abstract Number: 595

What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study
Abstract Number: 590

What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?
Abstract Number: 1979

What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling
Abstract Number: 1321

What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative
Abstract Number: 2088

When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis
Abstract Number: 471

When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA
Abstract Number: 2402

Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?
Abstract Number: 855

Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?
Abstract Number: 271

Who Prescribed Which Osteoporosis Medication to Whom
Abstract Number: 1232

Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation
Abstract Number: 1962

Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs
Abstract Number: 240

Whom Do Patients with Fibromyalgia Turn to for Emotional Support?
Abstract Number: 2084

Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017
Abstract Number: 169

Wikipedia as a Source of Health Information for the Public: Systematic Analysis of Quality and Readability of 8 Common Rheumatic Diseases Articles
Abstract Number: 2351

Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Abstract Number: 1532

Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study
Abstract Number: 2525

Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 497

Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population
Abstract Number: 418

Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study
Abstract Number: 163

Workforce Survey: Career Trends of Combined Adult and Pediatric Rheumatology Fellowship Graduates
Abstract Number: 567

Worse Outcomes for Female Patients with Axial Spondyloarthropathy
Abstract Number: 1727

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Abstract Number: 1872

Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u v [w] x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].